Lundbeck and Novo were among the participants in the immuno-oncology drug developer's series B round having backed its series A four years ago.
Denmark-based cancer therapy developer IO Biotech secured €127m ($154m) on Wednesday in a series B round featuring pharmaceutical companies Novo and Lundbeck, which participated through Lundbeckfonden Emerge and Novo Seeds respectively.
HBM Healthcare Investments led the round, which included Sunstone Life Science Ventures, Vivo Capital, Kurma Partners, Avoro Capital, RA Capital Management, Samsara Biocapital, Idinvest Partners, PFM Health Sciences, Soleus Capital, Eir Ventures and Serrado Capital.
IO Biotech is developing immuno-oncology therapies that can recognise and eliminate tumour cells and…
